fashion -WSS

fashion

author：comprehensive 2025-09-29 13:46:28 - browse：2819

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Sweden knocks USA out of World Cup in penalty kicks

focus

WSS

Fed up with FDA, ALS advocates consider a take

PBMs drew scrutiny in House hearing — and so did pharma

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Doctors push to include dialysis machines in emergency stockpile

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Doctors are clamoring for more clarity on Paxlovid prescribing

leisure time

fashion

explore

Supreme Court strikes down use of affirmative action

Free Covid tests will again be offered to all U.S. households

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA panel to weigh safety of artificial wombs for preterm births

Walensky prepares to leave CDC — and Congress — behind

Kansas bar where gunfire wounded 9 last month closes permanently

Heart attack and stroke risk calculators need revising

Doctors are clamoring for more clarity on Paxlovid prescribing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pennsylvania man bitten on the head by bear during attack in his garage

leisure time

Failure, not just success, should guide future doctors

Kansas bar where gunfire wounded 9 last month closes permanently

People with substance use disorder deserve online privacy

Fed up with FDA, ALS advocates consider a take

A fugitive mob suspect in Greece is betrayed by his passion for hometown Naples soccer champions

How CRISPR works, explained in two minutes

focus

focus

focus

knowledge